These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 37366821)
21. In vitro models replicating the human intestinal epithelium for absorption and metabolism studies: A systematic review. Fedi A; Vitale C; Ponschin G; Ayehunie S; Fato M; Scaglione S J Control Release; 2021 Jul; 335():247-268. PubMed ID: 34033859 [TBL] [Abstract][Full Text] [Related]
22. Farewell to Animal Testing: Innovations on Human Intestinal Microphysiological Systems. Kang TH; Kim HJ Micromachines (Basel); 2016 Jun; 7(7):. PubMed ID: 30404281 [TBL] [Abstract][Full Text] [Related]
23. Human gut microbiota plays a role in the metabolism of drugs. Jourova L; Anzenbacher P; Anzenbacherova E Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Sep; 160(3):317-26. PubMed ID: 27485182 [TBL] [Abstract][Full Text] [Related]
24. Pathomimetic modeling of human intestinal diseases and underlying host-gut microbiome interactions in a gut-on-a-chip. Shin W; Kim HJ Methods Cell Biol; 2018; 146():135-148. PubMed ID: 30037458 [TBL] [Abstract][Full Text] [Related]
25. Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue. Incecayir T; Sun J; Tsume Y; Xu H; Gose T; Nakanishi T; Tamai I; Hilfinger J; Lipka E; Amidon GL J Pharm Sci; 2016 Feb; 105(2):925-934. PubMed ID: 26869437 [TBL] [Abstract][Full Text] [Related]
26. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Peters SA Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054 [TBL] [Abstract][Full Text] [Related]
27. Trust your gut: Bioavailability and bioaccessibility of dietary compounds. Rodrigues DB; Marques MC; Hacke A; Loubet Filho PS; Cazarin CBB; Mariutti LRB Curr Res Food Sci; 2022; 5():228-233. PubMed ID: 35106487 [TBL] [Abstract][Full Text] [Related]
28. Contributions of the microbiome to intestinal inflammation in a gut-on-a-chip. Jeon MS; Choi YY; Mo SJ; Ha JH; Lee YS; Lee HU; Park SD; Shim JJ; Lee JL; Chung BG Nano Converg; 2022 Feb; 9(1):8. PubMed ID: 35133522 [TBL] [Abstract][Full Text] [Related]
29. Gut-on-a-Chip Models: Current and Future Perspectives for Host-Microbial Interactions Research. Morelli M; Kurek D; Ng CP; Queiroz K Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831155 [TBL] [Abstract][Full Text] [Related]
30. Intestinal Pearce SC; Coia HG; Karl JP; Pantoja-Feliciano IG; Zachos NC; Racicot K Front Physiol; 2018; 9():1584. PubMed ID: 30483150 [TBL] [Abstract][Full Text] [Related]
31. In vitro hepatic steatosis model based on gut-liver-on-a-chip. Jeon JW; Lee SH; Kim D; Sung JH Biotechnol Prog; 2021 May; 37(3):e3121. PubMed ID: 33393209 [TBL] [Abstract][Full Text] [Related]
32. Development of a Gut-On-A-Chip Model for High Throughput Disease Modeling and Drug Discovery. Beaurivage C; Naumovska E; Chang YX; Elstak ED; Nicolas A; Wouters H; van Moolenbroek G; Lanz HL; Trietsch SJ; Joore J; Vulto P; Janssen RAJ; Erdmann KS; Stallen J; Kurek D Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31726729 [TBL] [Abstract][Full Text] [Related]
33. Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism. Enright EF; Griffin BT; Gahan CGM; Joyce SA Pharmacol Res; 2018 Jul; 133():170-186. PubMed ID: 29660405 [TBL] [Abstract][Full Text] [Related]
34. Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective. Wilson CG; Aarons L; Augustijns P; Brouwers J; Darwich AS; De Waal T; Garbacz G; Hansmann S; Hoc D; Ivanova A; Koziolek M; Reppas C; Schick P; Vertzoni M; García-Horsman JA Eur J Pharm Sci; 2022 May; 172():106100. PubMed ID: 34936937 [TBL] [Abstract][Full Text] [Related]
35. Organs-on-a-chip: Current applications and consideration points for in vitro ADME-Tox studies. Ishida S Drug Metab Pharmacokinet; 2018 Feb; 33(1):49-54. PubMed ID: 29398302 [TBL] [Abstract][Full Text] [Related]
36. Intestinal Models for Personalized Medicine: from Conventional Models to Microfluidic Primary Intestine-on-a-chip. Li XG; Chen MX; Zhao SQ; Wang XQ Stem Cell Rev Rep; 2022 Aug; 18(6):2137-2151. PubMed ID: 34181185 [TBL] [Abstract][Full Text] [Related]
37. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Shen DD; Kunze KL; Thummel KE Adv Drug Deliv Rev; 1997 Sep; 27(2-3):99-127. PubMed ID: 10837554 [TBL] [Abstract][Full Text] [Related]
38. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140 [TBL] [Abstract][Full Text] [Related]
39. Microfluidic chip for culturing intestinal epithelial cell layers: Characterization and comparison of drug transport between dynamic and static models. Kulthong K; Duivenvoorde L; Sun H; Confederat S; Wu J; Spenkelink B; de Haan L; Marin V; van der Zande M; Bouwmeester H Toxicol In Vitro; 2020 Jun; 65():104815. PubMed ID: 32119998 [TBL] [Abstract][Full Text] [Related]
40. Drug Screening, Oral Bioavailability and Regulatory Aspects: A Need for Human Organoids. Zietek T; Boomgaarden WAD; Rath E Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452240 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]